Potential Pfizer-Allergan Deal Reignites Inversion Scrutiny
Pharmaceutical giant Pfizer's latest cross-border pursuit is already reigniting the discussion of so-called inversions roughly a year after rules surrounding the tax-motivated deal structure were tightened, posing a potential threat to...To view the full article, register now.
Already a subscriber? Click here to view full article